Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02030561
Recruitment Status : Unknown
Verified June 2016 by National University Hospital, Singapore.
Recruitment status was:  Recruiting
First Posted : January 8, 2014
Last Update Posted : June 22, 2016
Sponsor:
Collaborator:
National University, Singapore
Information provided by (Responsible Party):
National University Hospital, Singapore

Brief Summary:
This study will determine the safety and efficacy of expanded activated autologous NK cells administered after Trastuzumab in patients with HER2-positive breast or gastric cancer. It will also provide valuable insights of the role of NK cell infusions in adult solid tumors.

Condition or disease Intervention/treatment Phase
Breast Cancer Gastric Cancer Drug: Trastuzumab + NK cells Phase 1 Phase 2

Detailed Description:
Recently, targeted immunotherapies have become part of the therapeutic arsenal in adult solid tumors, and have shown promising activity in melanomas and prostate cancers. Trastuzumab is a monoclonal antibody that targets HER2 and is used routinely in combination with chemotherapy in HER2 over-expressing breast and gastric cancer. Trastuzumab is known to induce antibody dependent cell cytotoxicity (ADCC), among its various mechanisms for tumor cell kill. As such, trastuzumab may suitably be combined with immunotherapy as a strategy to harness the host's immune system against HER2-positive tumor cells.There is mounting evidence that natural killer (NK) cells have powerful anti-cancer activity. In patients with leukemia undergoing allogeneic hematopoietic stem cell transplant, several studies have demonstrated NK-mediated anti-leukemic activity. Allogeneic NK cell infusions in patients with primary refractory or multiple-relapsed leukemia have been shown to be well tolerated and void of graft-versus-host disease (GVHD) effects. In this study, we seek to enhance the antitumor activity of a commonly used antibody to treat HER2+ breast and gastric cancer, trastuzumab, administered in combination with infusion of activated and expanded autologous NK cells.This is a lead-in phase I followed by a phase II study. Up to 9 patients will be enrolled in phase I to test two different doses of NK cells to be infused into the patient. This will then be followed by a phase II study where 20 patients will be enrolled. Eligible patients will undergo apheresis about 9 days (up to 11 days) prior to cycle 1 therapy to harvest NK cells. The collected NK cells will be expanded and activated ex vivo. On day 1 of cycle 1, the patient will receive herceptin and subcutaneous IL2, followed by NK cell infusion on day 2 of cycle 1. This will then be followed by 5 doses of s/c IL2 three times a week to keep the NK cells activated in vivo. The patient will then receive three more cycles of herceptin (every 21 days). In patients who achieve objective tumor response after cycle 2 or cycle 4, a second NK cell infusion along with s/c IL2 will be administered with cycle 4 or cycle 6 herceptin respectively.This study will determine the safety and efficacy of this novel therapeutic strategy in HER2 positive breast and gastric cancer. It will also provide valuable insights of the role of NK cell infusions in adult solid tumors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
Study Start Date : January 2014
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : August 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: Trastuzumab + NK cells

During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.

From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.

Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1.

Drug: Trastuzumab + NK cells
Other Name: Herceptin




Primary Outcome Measures :
  1. Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: Up to 12-18 weeks ]

    During cycle 1 (21 days) and for at least 21 days following a second NK cell infusion if administered:

    - Patients will be reviewed twice a week with

    • Limited physical examination to include blood pressure, heart rate, weight
    • Full blood count, renal function and liver function tests
    • Toxicity rating using the NCI CTC scale
    • Concomitant medication notation and number of units required for transfusions

    Any significant abnormalities or significant toxicities have to be followed until recovery to baseline or 30 days after patient withdraws from the study, whichever occurs later.

    During other cycles when only trastuzumab is administered (without NK cells infusion or IL-2) Patients will be reviewed once every cycle of every 3-weekly cycle


  2. Duration of Tumor Response Measure [ Time Frame: Up to 36 months ]
    Among tumor responders, the duration of tumor response is measured from the date of enrolment until the first date of documented disease progression or death due to any cause, whichever occurs first. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.

  3. Time-to-Event Outcome Measure [ Time Frame: Up to 36 months ]
    Time to documented disease progression is defined as the time from the date of enrolment to the first date of documented disease progression. Time to documented disease progression will be censored at the date of death for patients who have not had documented disease progression. For patients who are still alive at the time of analysis and who have not had documented disease progression, time to documented disease progression will be censored at the date of the last follow-up visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-65
  2. Histologically confirmed diagnosis of HER2-positive breast or gastric cancer (defined as IHC 3+ or HER2 FISH amplification ratio >2.2)
  3. Metastatic disease
  4. Presence of measurable tumour by RECIST 1.1 criteria
  5. Must have failed at least two lines of trastuzumab-containing systemic therapy (documented relapse while receiving adjuvant or neoadjuvant trastuzumab for HER2 positive breast cancer is eligible)
  6. At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy
  7. Left ventricular ejection fraction ≥50%
  8. Adequate organ function ANC ≥ 1500/µL Platelet count ≥ 100,000/µL Creatinine clearance ≥60ml/minute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 2 x upper limit normal ALT ≤ 2 x upper limit normal
  9. ECOG performance status of 0-1
  10. Life expectancy of at least 60 days
  11. Negative serum or urine pregnancy test result within 14 days prior to enrolment for women who are of childbearing potential
  12. Ability to provide informed consent. Otherwise, a legally authorized representative (LAR) must be present throughout the consent process and is allowed to give consent on the patient's behalf.
  13. Patients with reproductive potential must agree to use an approved contraceptive method
  14. Ability to comply with study procedures

Exclusion Criteria:

  1. Treatment within the last 30 days with any investigational drug
  2. Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy
  3. Major surgery within 28 days of study drug administration
  4. Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
  5. Lactating or pregnant.
  6. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator; serious cardiac illness or medical conditions including but not limited to:

    • Patients with dyspnea at rest.
    • History of documented congestive heart failure
    • High risk uncontrolled arrhythmias
    • Angina pectoris requiring a medicinal product
    • Clinically significant valvular disease
    • Evidence of transmural infarction on ECG
    • Poorly controlled hypertension
  7. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment
  8. Symptomatic brain metastases
  9. Receipt of steroids during time period of 3 days prior to expanded NK cell infusion to 30 days after infusion (i.e. day -3 to day +30).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02030561


Contacts
Layout table for location contacts
Contact: Soo Chin Lee, MBBS (65) 6779 5555 Soo_Chin_Lee@nuhs.edu.sg
Contact: Joan Phee (65) 6772 2404 Joan_Phee@nuhs.edu.sg

Locations
Layout table for location information
Singapore
National University Hospital Recruiting
Singapore, Singapore, 119228
Contact: Soo Chin Lee, MBBS    +65 6779 5555    Soo_Chin_Lee@nuhs.edu.sg   
Sub-Investigator: Dario Campana, MBBS         
National University Hospital Not yet recruiting
Singapore, Singapore, 119228
Contact: Soo Chin Lee, MBBS    (65) 6779 5555    Soo_Chin_Lee@nuhs.edu.sg   
Principal Investigator: Soo Chin Lee, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
National University, Singapore
Investigators
Layout table for investigator information
Principal Investigator: Soo Chin Lee, MBBS National University Hospital, Singapore

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National University Hospital, Singapore
ClinicalTrials.gov Identifier: NCT02030561     History of Changes
Other Study ID Numbers: MC01/21/13
2013/00566 ( Other Identifier: Singapore NHG Domain Specific Review Boards )
First Posted: January 8, 2014    Key Record Dates
Last Update Posted: June 22, 2016
Last Verified: June 2016

Keywords provided by National University Hospital, Singapore:
NK cells
trastuzumab
immunotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents